BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Nelson CS, Baraniak I, Lilleri D, Reeves MB, Griffiths PD, Permar SR. Immune Correlates of Protection Against Human Cytomegalovirus Acquisition, Replication, and Disease. J Infect Dis 2020;221:S45-59. [PMID: 32134477 DOI: 10.1093/infdis/jiz428] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Spencer Clinton JL, Hoornweg TE, Tan J, Peng R, Schaftenaar W, Rutten VPMG, de Haan CAM, Ling PD. EEHV1A glycoprotein B subunit vaccine elicits humoral and cell-mediated immune responses in mice. Vaccine 2022:S0264-410X(22)00891-X. [PMID: 35879117 DOI: 10.1016/j.vaccine.2022.07.016] [Reference Citation Analysis]
2 Majewska A, Mlynarczyk-Bonikowska B. 40 Years after the Registration of Acyclovir: Do We Need New Anti-Herpetic Drugs? Int J Mol Sci 2022;23:3431. [PMID: 35408788 DOI: 10.3390/ijms23073431] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Ataya M, Redondo-Pachón D, Llinàs-Mallol L, Yélamos J, Alari-Pahissa E, Pérez-Sáez MJ, Altadill M, Raïch-Regué D, Vilches C, Pascual J, Crespo M, López-Botet M. Long-Term Evolution of the Adaptive NKG2C+ NK Cell Response to Cytomegalovirus Infection in Kidney Transplantation: An Insight on the Diversity of Host-Pathogen Interaction. J Immunol 2021;207:1882-90. [PMID: 34470855 DOI: 10.4049/jimmunol.2100055] [Reference Citation Analysis]
4 Struble EB, Murata H, Komatsu T, Scott D. Immune Prophylaxis and Therapy for Human Cytomegalovirus Infection. Int J Mol Sci 2021;22:8728. [PMID: 34445434 DOI: 10.3390/ijms22168728] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
5 Li L, Freed DC, Liu Y, Li F, Barrett DF, Xiong W, Ye X, Adler SP, Rupp RE, Wang D, Zhang N, Fu TM, An Z. A conditionally replication-defective cytomegalovirus vaccine elicits potent and diverse functional monoclonal antibodies in a phase I clinical trial. NPJ Vaccines 2021;6:79. [PMID: 34078915 DOI: 10.1038/s41541-021-00342-3] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
6 Feldmann S, Grimm I, Stöhr D, Antonini C, Lischka P, Sinzger C, Stegmann C. Targeted mutagenesis on PDGFRα-Fc identifies amino acid modifications that allow efficient inhibition of HCMV infection while abolishing PDGF sequestration. PLoS Pathog 2021;17:e1009471. [PMID: 33780515 DOI: 10.1371/journal.ppat.1009471] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
7 Perotti M, Marcandalli J, Demurtas D, Sallusto F, Perez L. Rationally designed Human Cytomegalovirus gB nanoparticle vaccine with improved immunogenicity. PLoS Pathog 2020;16:e1009169. [PMID: 33370407 DOI: 10.1371/journal.ppat.1009169] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
8 Materne EC, Lilleri D, Garofoli F, Lombardi G, Furione M, Zavattoni M, Gibson L. Cytomegalovirus-Specific T Cell Epitope Recognition in Congenital Cytomegalovirus Mother-Infant Pairs. Front Immunol 2020;11:568217. [PMID: 33329532 DOI: 10.3389/fimmu.2020.568217] [Reference Citation Analysis]
9 Nelson CS, Jenks JA, Pardi N, Goodwin M, Roark H, Edwards W, McLellan JS, Pollara J, Weissman D, Permar SR. Human Cytomegalovirus Glycoprotein B Nucleoside-Modified mRNA Vaccine Elicits Antibody Responses with Greater Durability and Breadth than MF59-Adjuvanted gB Protein Immunization. J Virol 2020;94:e00186-20. [PMID: 32051265 DOI: 10.1128/JVI.00186-20] [Cited by in Crossref: 13] [Cited by in F6Publishing: 20] [Article Influence: 6.5] [Reference Citation Analysis]